Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Current Assets (2016 - 2026)

Agios Pharmaceuticals (AGIO) has disclosed Current Assets for 15 consecutive years, with $834.8 million as the latest value for Q1 2026.

  • For Q1 2026, Current Assets fell 13.81% year-over-year to $834.8 million; the TTM value through Mar 2026 reached $834.8 million, down 13.81%, while the annual FY2025 figure was $942.1 million, 2.44% down from the prior year.
  • Current Assets hit $834.8 million in Q1 2026 for Agios Pharmaceuticals, down from $942.1 million in the prior quarter.
  • Across five years, Current Assets topped out at $1.1 billion in Q3 2024 and bottomed at $632.1 million in Q2 2024.
  • Average Current Assets over 5 years is $863.7 million, with a median of $834.8 million recorded in 2026.
  • Year-over-year, Current Assets plummeted 58.59% in 2022 and then skyrocketed 61.28% in 2025.
  • Agios Pharmaceuticals' Current Assets stood at $832.8 million in 2022, then rose by 0.13% to $833.8 million in 2023, then increased by 15.8% to $965.6 million in 2024, then dropped by 2.44% to $942.1 million in 2025, then dropped by 11.38% to $834.8 million in 2026.
  • According to Business Quant data, Current Assets over the past three periods came in at $834.8 million, $942.1 million, and $1.0 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.